Skip to main content
    D

    Dare Bioscience Inc (DARE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.58
    -0.07 (-11.13%)

    Market Cap: $12.93M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Dare Bioscience Inc (DARE) Earnings: Report Dates and Results

    Updated Aug 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Dare Bioscience (DARE) is expected to report earnings on Mar 24, 2027. In the quarter ended Jun 30, 2026, Dare Bioscience reported EPS of -$0.20, above the -$0.33 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    59%(22/37)
    Avg Surprise
    +7.35%
    Streak
    6 Q

    Upcoming Estimates

    Reports Mar 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.24
    Range-$0.29 - -$0.17
    5 analysts
    Revenue Consensus
    $366.52K
    RangeN/A
    5 analysts

    Next Report

    DARE has an expected report date of Mar 24, 2027.

    DARE Earnings Call

    The latest DARE earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 38 quarters below that had an estimate, DARE beat 23, missed 13 and matched 2. The widest gap in the table came in the quarter ended Dec 31, 2020, when EPS landed 115.38% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$0.20-$0.33-$0.40 - -$0.24+39.39%BeatN/A31 up, 0 downAug 13, 2026$187546
    Mar 31, 2026-$0.20-$0.30-$0.33 - -$0.28+33.33%BeatN/A21 up, 0 downMay 14, 2026$152455
    Dec 31, 2025-$0.10-$0.42-$0.64 - -$0.24+76.05%BeatN/A34 up, 0 downMar 26, 2026$1.02M
    Sep 30, 2025-$0.28-$0.40-$0.47 - -$0.32+30.00%BeatN/A44 up, 0 downNov 13, 2025$2262
    Jun 30, 2025-$0.45-$0.58-$0.74 - -$0.48+22.41%BeatN/A40 up, 1 downAug 14, 2025N/A
    Mar 31, 2025-$0.50-$0.58-$0.68 - -$0.49+13.79%BeatN/A31 up, 1 downMay 13, 2025N/A
    Dec 31, 2024-$0.65-$0.63-$0.80 - -$0.52-2.64%MissN/A31 up, 1 downMar 31, 2025N/A
    Sep 30, 2024-$0.55-$0.71-$0.93 - -$0.54+22.54%BeatN/A31 up, 1 downNov 14, 2024$41691
    Jun 30, 2024-$0.89-$0.66-$0.84 - $1.92-34.85%MissN/A40 up, 0 downAug 12, 2024$22438
    Mar 31, 2024-$0.84-$0.72-$0.72 - -$0.72-16.67%MissN/A20 up, 0 downMay 14, 2024$9302
    Dec 31, 2023-$0.06-$0.10-$0.19 - -$0.06+40.00%BeatN/A50 up, 0 downMar 28, 2024$1.81M
    Sep 30, 2023-$1.08-$1.20-$1.32 - -$0.96+10.00%BeatN/A51 up, 0 downNov 9, 2023$1.00M
    Jun 30, 2023-$1.20-$1.08-$1.44 - -$0.84-11.11%Miss-2100.0%60 up, 0 downAug 10, 2023N/A
    Mar 31, 2023-$1.08-$1.20-$1.56 - -$0.84+10.00%BeatN/A30 up, 0 downMay 11, 2023N/A
    Dec 31, 2022-$0.19-$0.14-$0.19 - -$0.09-35.71%MissN/A60 up, 0 downMar 30, 2023$10.00B
    Sep 30, 2022-$0.96-$1.36-$1.56 - -$1.08+29.41%BeatN/A40 up, 0 downNov 10, 2022N/A
    Jun 30, 2022$0.06-$0.76-$1.32 - $0.12+107.89%BeatN/A30 up, 0 downAug 9, 2022$10.00M
    Mar 31, 2022-$0.10-$0.14-$0.20 - -$0.10+28.57%BeatN/A40 up, 0 downMay 12, 2022N/A
    Dec 31, 2021-$2.16-$2.16-$2.76 - -$0.120.00%In lineN/A50 up, 0 downMar 31, 2022N/A
    Sep 30, 2021-$2.16-$2.10-$2.16 - -$0.12-2.86%MissN/A4N/ANov 10, 2021N/A
    Jun 30, 2021-$2.16-$1.96-$2.04 - -$1.80-10.20%MissN/A4N/AAug 12, 2021N/A
    Mar 31, 2021-$2.07-$2.96-$4.32 - -$1.80+30.07%BeatN/A4N/AMay 13, 2021N/A
    Dec 31, 2020-$0.28-$0.13-$0.23 - $0.09-115.38%MissN/A5N/AMar 30, 2021N/A
    Sep 30, 2020-$2.88-$2.22-$2.76 - -$1.32-29.73%MissN/A5N/ANov 12, 2020N/A
    Jun 30, 2020-$3.24-$2.04-$2.16 - -$1.20-58.82%MissN/A5N/AAug 12, 2020N/A
    Mar 31, 2020-$2.16-$3.92-$7.92 - -$1.92+44.90%BeatN/A4N/AMay 14, 2020N/A
    Dec 31, 2019-$0.21-$0.18-$0.27 - -$0.13-16.67%MissN/A5N/AMar 30, 2020N/A
    Sep 30, 2019-$2.40-$2.48-$2.88 - -$2.28+3.23%BeatN/A3N/ANov 14, 2019N/A
    Jun 30, 2019-$3.48-$2.34-$2.40 - -$2.28-48.72%MissN/A3N/AAug 14, 2019N/A
    Mar 31, 2019-$3.24-$3.96-$3.96 - -$3.12+18.18%BeatN/A3N/AApr 1, 2019N/A
    Dec 31, 2018-$0.25-$0.27-$0.29 - -$0.23+7.41%BeatN/A3N/AMar 31, 2019N/A
    Sep 30, 2018-$2.76-$2.96N/A+6.76%BeatN/AN/AN/ANov 13, 2018N/A
    Jun 30, 2018-$3.84-$2.82N/A-36.17%MissN/AN/AN/AAug 13, 2018N/A
    Mar 31, 2018-$0.88-$0.88N/A0.00%In lineN/AN/AN/AMay 14, 2018N/A
    Dec 31, 2017-$1.48-$3.10N/A+52.26%BeatN/AN/AN/AMar 28, 2018N/A
    Sep 30, 2017-$0.33N/AN/AN/AN/AN/AN/AN/ANov 13, 2017N/A
    Jun 30, 2017-$0.20N/AN/AN/AN/AN/AN/AN/AAug 14, 2017N/A
    Mar 31, 2017-$2.70-$3.10N/A+12.90%BeatN/AN/AN/AMay 12, 2017N/A
    Dec 31, 2016-$1.60-$3.35N/A+52.24%BeatN/AN/AN/AMar 31, 2017$766000
    Sep 30, 2016-$3.60-$4.08N/A+11.76%BeatN/AN/AN/ANov 3, 2016N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.33, after -$2.93 the year before. It was -$14.10 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.33N/A
    Dec 31, 2024-$2.93N/A
    Dec 31, 2023-$3.42N/A
    Dec 31, 2022-$1.19N/A
    Dec 31, 2021-$8.55N/A
    Dec 31, 2020-$8.56N/A
    Dec 31, 2019-$9.33N/A
    Dec 31, 2018-$7.73N/A
    Dec 31, 2017-$4.71N/A
    Dec 31, 2016-$14.10N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 4,300 words across 4 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20264,3494
    2026Q1Mar 31, 20265,7634
    2025Q3Sep 30, 20254,7305
    2025Q2Jun 30, 20252,4693
    2025Q1Mar 31, 20255,6535
    2024Q3Sep 30, 20245,7426
    2024Q2Jun 30, 20243,9695

    2026Q2 Earnings Call

    Opening remarks

    MarDee J. Haring-Layton Chief Accounting Officer Good afternoon, and welcome. Today, we will review our financial results, provide updates on our commercial products and clinical pipeline and discuss the continued execution of our expanded business strategy. That strategy includes a dual path approach: commercializing proprietary formulations through 503B compounding while pursuing FDA approval and advancing select solutions as branded consumer health products that do not require a prescription. In all cases, our goal is to bring innovative women's health solutions to market as efficiently and quickly as possible. I would like to remind you that today's discussion will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 2000. Any statements made during this call that are not actual statements of historical facts should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings, including our quarterly report on Form 10-Q for the quarter ended 06/30/2026, which was filed today, and our annual report on Form 10-K for the year ended 12/31/2025. Please note that the content of this call includes time-sensitive information that is current only as of today, 08/13/2026. Dare undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call, except as required by law. I would also like to point out that when we use the term 503B compounding during this discussion, we are referring to compounding drug products by outsourcing facilities registered under section 503B of the federal Food, Drug, and Cosmetic Act using drug substances on the FDA's interim category 1 list. I would now like to turn the call over to Sabrina.

    Sabrina Martucci Johnson President and Chief Executive Officer Thank you, MarDee, and good afternoon, everyone, and thank you for joining us. For more than 10 years, Dare has been building towards this moment. We built Dare on a simple conviction: women's health is an investment-grade category — not a niche, not a side project. A category worth building, funding, and holding accountable for delivering the health care options women deserve. Every asset we developed, every trial we ran, every grant we secured, every collaboration we have negotiated, all of it has been directed towards this one purpose: closing the gap between promising science and real-world solutions for women. And over the past few months, that strategy crossed an important threshold. We did not stop being a science-driven development company. We added something new: commercial execution. That distinction matters.

    Frequently Asked Questions About DARE

    When is Dare Bioscience's next earnings date?

    Dare Bioscience's next earnings report is expected for Mar 24, 2027.

    Did DARE beat earnings estimates last quarter?

    Yes. Dare Bioscience reported EPS of -$0.20 for the quarter ended Jun 30, 2026, above the -$0.33 estimate, a 39.39% surprise.

    What EPS do analysts expect from DARE next quarter?

    The consensus EPS estimate for Dare Bioscience for the quarter ending Dec 31, 2026 is -$0.24 from 5 analysts, with estimates from -$0.29 to -$0.17.

    How often does DARE beat earnings estimates?

    Dare Bioscience beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +29.36%.